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Abstract
 
Angiotensin II (ANG II) is a potent vasoconstrictor and
growth promoter. Quantitative receptor autoradiography
using the nonselective radioligand [
 
125
 
I]ANG II and sub-
type-selective competing compounds demonstrated the pre-
sence of both ANG II receptor (AT)
 
1
 
 and AT
 
2
 
 receptor rec-
ognition sites. In addition, a relatively small population of
apparently non-AT
 
1
 
/non-AT
 
2
 
 sites was identified that may
represent a novel high affinity ANG II recognition site in
human placenta. Using placental membrane preparations,
the AT
 
2
 
 receptor antagonist PD123177 failed to compete for
[
 
3
 
H]ANG II binding at relevant concentrations, whereas the
AT
 
1
 
 receptor antagonist losartan competed in a monophasic
manner for all the specific binding, suggesting that the non-
AT
 
1
 
/non-AT
 
2
 
 recognition site identified using autoradiogra-
phy may be a cytosolic binding site. AT
 
1
 
 receptor binding
was significantly reduced (
 
P 
 
, 
 
0.02) in intraeuterine growth
restriction (IUGR) pregnancies. Western blot analysis con-
firmed this showing a reduction in AT
 
1
 
 receptor protein. In
situ hybridization and immunocytochemistry revealed that
AT
 
1
 
 receptor mRNA and protein were localized throughout
pregnancy in the cytotrophoblast, syncytiotrophoblast, and
extravillous trophoblast, as well as in or around the blood
vessels of placental villi. The intensity of the hybridization
signal for AT
 
1
 
 receptor mRNA over the syncytium was re-
duced in IUGR. ANG II evoked a rapid and concentration-
dependent release of NO in first trimester cytotrophoblast-like
cells that was abolished by the inclusion of the competitive
NOS inhibitor N
 
G
 
-monomethyl-
 
L
 
-arginine. Neither losartan
nor PD123177 alone significantly inhibited ANG II–evoked
NO release, and when cells were stimulated with ANG II in
the presence of losartan (10 
 
m
 
M) and PD123177 (10 
 
m
 
M) in
combination, NO release was significantly inhibited (
 
P 
 
,
 
0.05). These observations also suggest, for the first time, the
existence of a cross-talk between AT
 
1
 
 or AT
 
2
 
 receptors in
trophoblast and that the reduction in placental AT
 
1
 
 recep-
tors in IUGR may, in part, account for poor placental func-
tion in this disorder. (
 
J. Clin. Invest.
 
 1998. 101:442–454.)
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Introduction
 
Successful placentation requires an orchestrated development
of a low impedance utero-placental circulation and an ade-
quate feto-placental circulation to meet the increasing demand
of the growing fetus for oxygen and nutrients. Any disturbance
in the balance between these circulations will alter intraplacen-
tal exchange. As the feto-placental vasculature lacks auto-
nomic innervation (1), the control of this vascular bed must
involve humoral mechanisms. The placenta is capable of pro-
ducing both the potent vasoconstrictor angiotensin II (ANG
II)
 
1
 
 and the potent vasodilator and inhibitor of platelet aggre-
gation nitric oxide (NO); the balance between these could con-
trol feto-placental hemodynamics, ensuring adequate placen-
tal blood flow, fetal nutrition, and oxygenation. Vascular
insufficiency arising from abnormal placentation, as is evident
by the reduction in umbilical blood flow, hypovascularity, and
reduced placental villous development, may affect the fetus
(2). This can lead to intrauterine growth restriction (IUGR), in
which the risk of fetal death is an order of magnitude higher
than in appropriately grown fetuses.
Angiotensinogen, as well as renin and ANG-converting en-
zyme, has been found in high concentrations in human pla-
centa (3), supporting the concept of a local renin–ANG sys-
tem. ANG I is converted to the biologically active octapeptide
ANG II by ANG-converting enzyme (ACE) in the feto-pla-
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cental bed (4) and has potent vasoconstrictor activity in the
feto-placental circulation (5). In the ovine fetus, infusion of
ANG II markedly reduces feto-placental perfusion and causes
a redistribution of blood flow to the heart and brain at the ex-
pense of renal, hepatic, and gut perfusion (6). Experimentally
induced hypoxemia stimulates the release of renin and subse-
quent generation of ANG II in the ovine fetus (7) and intra-
uterine growth restriction (IUGR) is associated with increased
plasma renin activity (8) and fetal hypoxemia (9).
ANG II interacts with specific, high-affinity receptors on
the surface of target cells to exert its biological effects. The
genes encoding the AT
 
1 
 
(10) and AT
 
2
 
 (11) receptors have been
cloned and the proteins share only a 32% overall amino acid
sequence homology, although as is common, the transmem-
brane regions show a somewhat higher degree of homology.
The occurrence and proportion of the AT
 
1
 
 and AT
 
2
 
 receptor
subtypes vary significantly among different tissues and organs
of the same species (12) and also in the same tissue and organs
of different species (13). Experiments with the AT
 
1
 
 receptor-
selective antagonist losartan (previously designated DuP753)
indicate that this subtype is responsible for the vast majority of
the hemodynamic and cardiovascular effects of ANG II (14).
The biological function of AT
 
2
 
 receptor is not clear, although
AT
 
2
 
 receptor is abundantly expressed in fetal tissues (15), sug-
gesting that the AT
 
2
 
 receptor is associated with differentiation
and development. In recent mouse studies, targeted disruption
of the AT
 
2
 
 receptor gene resulted in a significant increase in
blood pressure and increased sensitivity to the pressor action
of ANG II indicating that ANG II acts via the two receptors
with opposing effects and that there may be functional interac-
tion between the two receptor subtypes (16, 17). Indeed, Gel-
band et al. (18) have suggested the existence of a cross-talk be-
tween AT
 
1
 
 and AT
 
2
 
 receptors in catecholaminergic neurons.
The feto-placental unit is a source of vasorelaxants such as
NO and parathyroid hormone-related protein (PTHrP), both
potent vasorelaxants. Formation of NO is achieved by the con-
version of 
 
L
 
-arginine to 
 
L
 
-citrulline by the enzyme NO syn-
thase (NOS) in the presence of molecular oxygen, NADPH,
and cofactors (for review see reference 19). Human placenta
selectively expresses the endothelial NOS isoform that is
present in human placental vasculature (20) and syncytiotro-
phoblast (21, 22). NO is released from trophoblast cells in cul-
ture (23), and exogenous NO relaxes umbilical (24) and chori-
onic plate (25) artery preparation in vitro. NO attenuates the
actions of vasoconstrictors in the feto-placental circulation and
inhibition, either of NO synthesis or its action on vascular
smooth muscle, increases basal perfusion pressure in the iso-
lated human placental cotyledon (26, 27, 28). Like NO, bioac-
tive PTHrP was detected in human placenta (29, 30), and
PTHrP was shown to be localized in the brush border of the
syncytiotrophoblast and fetal vessels of placental villi (31).
PTHrP causes a concentration-dependent vasodilator effect in
the dually perfused placental cotyledons that have been pre-
constricted with a thromboxane mimetic U46619 (32).
This study demonstrates for the first time the cellular local-
ization of receptor protein and mRNA encoding the AT
 
1
 
 re-
ceptor in human placenta and that AT
 
1
 
 receptors are reduced
in severe IUGR placentae. In addition, it shows that ANG II
can stimulate placental NO and PTHrP release, and it identi-
fies an apparently non-AT
 
1
 
/non-AT
 
2
 
 high affinity ANG II rec-
ognition site in placental sections using receptor autoradio-
graphy.
 
Methods
 
Source of tissue
 
Human placental tissues were obtained from uncomplicated term
pregnancies delivered by elective cesarean section for breech presen-
tation or a recurring indication in otherwise uncomplicated pregnan-
cies. Placental tissue was also obtained from pregnancies complicated
by severe asymmetrical IUGR. Growth-restricted fetuses were pro-
spectively identified using ultrasound biometry and diagnosed by the
absence of umbilical artery end diastolic blood flow. Ethical commit-
tee approval was obtained from the South Birmingham Ethical Com-
mittee. After dissection, the tissue was wrapped in parafilm to pre-
vent dehydration, rapidly frozen over dry ice, and then stored at
 
2
 
80
 
8
 
C until they were either sectioned for in situ hybridization or au-
toradiography or homogenized. Placental tissue was also collected in
10% formalin, paraffin embedded, and then sectioned for immuno-
histochemical studies.
 
Preparation of tissue sections
 
Frozen placental tissue was surrounded in embedding medium (OCT
compound; Miles Inc., Kankakee, IL) before 20-
 
m
 
m sections were cut
using a cryostat (
 
2
 
17
 
8
 
C) and thaw mounted onto gelatin-coated glass
slides for receptor autoradiographic studies, and 10-
 
m
 
m sections were
cut and thaw-mounted onto poly-
 
L
 
-lysine–coated (Sigma Chemical
Co., Poole, UK) glass slides for in situ hybridization studies. Sections
were stored (
 
. 
 
2 wk) at 
 
2
 
80
 
8
 
C until used.
 
[
 
125
 
I]ANG II autoradiography
 
Receptor autoradiography studies were performed as previously de-
scribed (12). Slide-mounted placental sections (three/slide) were in-
cubated in incubation buffer that contained 0.1 nM [
 
125
 
I]-[5-
 
L
 
-isoleu-
cine]ANG II ([
 
125
 
I]ANG II, 2,000 Ci/mmol; Amersham International,
Little Chalfont, UK) in the absence (total binding) or presence of
competing compound (either 1.0 
 
m
 
M unlabeled ANG II, 1.0 
 
m
 
M
DuP753, and 1.0 
 
m
 
M PD123177 or 1.0 
 
m
 
M DuP753 plus 1.0 
 
m
 
M
PD123177) for 60 min at 25
 
8
 
C. Immediately after incubation, the tis-
sue sections were washed in ice-cold incubation buffer and dipped in
ice-cold distilled water to remove buffer salts. The sections were rap-
idly air dried and exposed to  [
 
3
 
H]-Hyperfilm (Amersham Interna-
tional) in x-ray cassettes together with [
 
125
 
I]standards (Amersham In-
ternational) for 10 d. Autoradiographic films were developed in
Kodak LX 24 developer and fixed in Kodak Unifix.
 
Quantitative image analysis
 
After the development of autoradiographic film, the silver grain den-
sity was assessed using image analysis (MCID, Imaging Research
Inc., St. Catherines, Ontario, Canada) from the three sections on each
slide and a mean value generated that represented
 
 n 
 
5 
 
1. The film
was quantified by reference to [
 
125
 
I]standards (fmol/mg tissue equiva-
lent values for intact gray matter; Amersham International). An un-
paired Student 
 
t
 
 test or ANOVA test followed by Dunnett’s test,
where appropriate, was applied to compare the changes in the mean
values of silver grain density between the two groups.
 
[
 
3
 
H]ANG II homogenate binding
 
Placental tissues were homogenized (Polytron setting 7, 10 s) in ice-
cold incubation buffer and centrifuged (48,000 
 
g
 
, 4
 
8
 
C, 10 min). The
pellet was gently resuspended in incubation buffer and recentrifuged
(48,000 
 
g
 
, 4
 
8
 
C, 10 min). The binding homogenate was formed by gen-
tle resuspension of the pellet in incubation buffer. The preparation of
the binding homogenate was performed immediately before assay.
For [
 
3
 
H]ANG II binding, test tubes in duplicate contained 150 
 
m
 
l
competing compound (or vehicle, incubation buffer) and 100 
 
m
 
l
[
 
3
 
H]ANG II (final concentration 80–120 pM). 250 
 
m
 
l homogenate was
added to initiate binding which was allowed to proceed for 60 min at
25
 
8
 
C before termination by rapid filtration through prewet (0.1% vol/
vol polyethyleneimine in incubation buffer) GF/B filters followed by
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washing (4
 
 3 
 
4 s) with ice-cold incubation buffer. Radioactivity was
assessed using a gamma counter.
 
Data analysis
 
Competition data were analyzed by computer-assisted iterative curve
fitting according to the equation; b 
 
5 
 
(B
 
max
 
[L]
 
n
 
)/ ([L]
 
n
 
 
 
1
 
 [K]
 
n
 
).
Where, b 
 
5 
 
bound radioligand, B
 
max
 
 
 
5 
 
maximum bound radioligand,
K 
 
5 
 
IC
 
50
 
 of competing compound, L 
 
5 
 
concentration of competing
compound and
 
 n 
 
5 
 
Hill number.
 
Western blot analysis
 
Protein was extracted from frozen placental tissue using high salt
buffer (0.4 M KCl, 20 mM Hepes, pH 7.4, 1 mM DTT, 20% glycerol,
0.5 mg/ml bacitracin, 40 
 
m
 
g/ml PMSF, 5 
 
m
 
g/ml pepstatin, 5 
 
m
 
g/ml leu-
peptin). Tissue homogenate was centrifuged at 12,000 rpm (3,000 
 
g
 
)
at 4
 
8
 
C for 10 min. The supernatant was stored at 
 
2
 
70
 
8
 
C until further
use. Protein concentration was determined using the Bio-Rad protein
assay (Bio-Rad Laboratories Inc., Hercules, CA) using BSA as stan-
dard. The nonradioactive enhanced chemiluminescence Western
blotting system (Amersham International) was used to detect AT
 
1
 
 re-
ceptor in placental samples as previously described (33). In brief, 50
 
m
 
g total protein was separated by electrophoresis on a polyacryl-
amide gel. The samples were loaded in a final volume of 25 
 
m
 
l with
sample buffer containing 0.002% bromophenol blue and electro-
phoresed at 50V for 
 
z
 
2 h. A kaleidoscope protein marker (Bio-Rad
Laboratories) was run alongside the samples. After electrophoresis
the protein was transferred onto a nitrocellulose membrane in a cool-
ing system (10
 
8
 
C) overnight at 36V. The filter was blocked to reduce
nonspecific binding of the antibody using Tris-buffered saline Tween
(TBS-T) containing 10% Marvel and 2.5% BSA for 4 h. After wash-
ing in TBS-T the membrane was incubated overnight at 4
 
8
 
C with the
AT
 
1
 
 receptor antibody at a dilution of 1:1,000. This high affinity rab-
bit polyclonal antibody was raised against a peptide corresponding to
amino acids 306–359 of the human AT
 
1
 
 receptor (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA and Autogen Bioclear UK Ltd.,
Wiltshire, UK). The filter was washed and incubated with the second-
ary anti–rabbit antibody for 1.5 h at room temperature. After a final
wash in TBS-T, the filter was incubated for 1 min at room tempera-
ture in detection reagent, immediately wrapped in saran wrap, and
then exposed for periods of 30 s, 1 min, 5 min, and 10 min to an x-ray
film.
 
In situ hybridization
 
A 45-base synthetic oligonucleotide probe complementary to the
bases 1821–1866 of the rat AT
 
1A
 
 was synthesized and used to locate
the mRNA that encode the receptor protein (34). This region of the
AT
 
1A 
 
gene was chosen because it was found to be divergent from
other homologous genes (10) and the probe was used previously to
localize the AT
 
1A
 
 mRNA in human endometrium (12). The oligo-
probe was 3
 
9 end-labeled either with [35S]dATP (for first trimester
and term placentae) by terminal transferase using a commercially
available kit (Du Pont, Stevenage, UK) or fluorescein-dUTP (for
term placentae) by using terminal deoxynucleotidyl transferase using
a oligo color kit (Amersham International) for nonradioactive in situ
hybridization. The reaction protocol was optimized to produce a tail
length with sufficient sensitivity without compromising the stringency
of the specific probe sequence. In situ hybridization was performed as
previously described using both radiolabeled (12) and fluorescein-
dUTP labeled (33) probe. As a negative control, some sections were
incubated in hybridization buffer containing labeled probe along with
100-fold excess of unlabeled probe. At the same time some sections
that were pretreated with 100 mg/ml of RNAse A (Sigma Chemical
Co.) for 1 h at 378C were also incubated with labeled probe.
Immunocytochemical studies
Serial 3-mm sections of formalin-fixed, paraffin-embedded tissue
from five normal term placentae were used for immunohistochemis-
try as previously described (12). Anti–human mouse monoclonal cy-
tokeratin, CD31, and macrophage CD68 antibodies were all pur-
chased from Dako Ltd. (Bucks, UK). Nonimmune goat serum (10%
in PBS) was used as a diluent of the primary antibody (1:25) to re-
duce nonspecific staining. Amplification of the primary antibody re-
action was achieved using a goat anti–rabbit secondary antibody (di-
luted 1:100 in PBS) for 30 min followed by a complex of streptavidin
(DAKO Ltd.) and biotinylated peroxidase (DAKO Ltd.) for an addi-
tional 30 min. Finally, the binding was visualized by the addition of
diaminobenzidine (Sigma Chemical Co.) and 0.01% hydrogen perox-
ide in PBS to form the insoluble antigen–antibody complex. Between
each step the sections were washed in PBS for 5 min. All incubations
of antiserum were performed at room temperature in a wet chamber
mounted on a rocking tray that ensured movement of antiserum over
the whole section. Sections were counterstained with Mayers hema-
toxylin, dehydrated, and mounted. To test the specificity of the im-
munohistochemical staining, the primary antibody was replaced with
goat nonimmune serum in control experiments.
Preparation and stimulation of cells for NO release
Increasing legislative and moral controls have recently been imposed
on the use of fetal tissues. A spontaneously transformed first trimes-
ter cytotrophoblast cell line was generated by repeated passaging of
trophoblast obtained from chorionic villous sampling. This cell line
provides a convenient model to investigate primary villous tropho-
blast (23). The cells were maintained in 75-cm2 flasks in Ham F12/
DME containing 15% (vol/vol) FCS, 1% L-glutamine, and 1% antibi-
otic mixture (10,000 IU penicillin and 10 mg streptomycin) at 378C in
95% O2 and 5% CO2 at 95% humidity. Subconfluent monolayers
were plated at a density of 300,000 cells/ml in 24-well culture plates
and grown in complete culture media for 24–36 h. Before agonist
stimulation, growth medium was removed and near confluent mono-
layers serum starved for 24 h. Stimulations were initiated by the addi-
tion of ANG II (Sigma Chemical Co.) in DME without FCS or ANG
II in the presence of either the ANG II subtype-selective receptor
antagonists or the nitric oxide synthesis inhibitor, NG-monomethyl-
L-arginine (L-NNA; Sigma Chemical Co.), or vehicle.
Measurement of NO release by chemiluminescence
For concentration dependence and time course experiments, stimula-
tions were initiated, for the times indicated, in a final volume of 0.5 ml
at 378C. For experiments with antagonists, cells were pretreated for
30 min and then stimulated with ANG II in a final volume of 0.5 ml at
378C for an additional 30 min. Reactions were terminated by removal
of the supernatant which was subsequently stored at 2808C for NO
analysis. Levels of NO were measured in the gas phase using a Siev-
ers NOA 270B chemiluminescence analyzer (Sievers NOA, Boulder,
CO) as previously described (23). The sensitivity of the NO assay was
1 pM. NO32 was not reduced in this system and was undetectable.
Tissue explant studies
Three to four small pieces of amnion or placenta (total weight of each
z 50 mg) were placed on a sterile inset support and incubated for 2 h
at 378C in 2 ml culture medium consisting of DME supplemented
with L-glutamine (2 mM), sodium pyruvate (1 mM), penicillin (100
U/ml), and streptomycin (50 U/ml). The media was replaced after 2 h
and the explants were incubated with increasing concentrations of
ANG II for a further 20 h at 378C in a humidified 5% CO2 incubator.
The medium was removed and centrifuged at 1,000 g for 5 min to re-
move cells and the supernatant was stored at 2808C until assay. Pro-
tein concentrations of extracts were determined by a protein kit (Bio-
Rad).
Assay for PTHrP
PTHrP was measured by immunoassay in conditioned media recon-
stituted in assay diluent (PBS, pH 7.4) containing 0.25% (wt/vol)
Polypep (Sigma Chemical Co.), 0.01% (wt/vol) sodium azide, and
0.1% (vol/vol) Triton X-100. PTHrP1–86 was measured by a two-site
immunoradiometric assay (IRMA) with antibodies specific for resi-
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dues 17–27 and 52–61 of PTHrP as previously described (35). The de-
tection limits of the IRMA was 0.23 pM. Unpaired Student t test was
applied to compare the changes in the mean values of PTHrP in re-
sponse to increasing concentrations of ANG II.
Drugs
Losartan DuP753 (2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2-(1H-tet-
razol-5-yl)biphenyl-4-yl)methyl]imidazole) and PD123177 (1-(4-amino-
3-methylphenyl)-methyl-5-diphenyl-acetyl-4, 5, 6, 7-tetrahydro-1H-imid-
azo [4, 5-C] pyridine-6-carboxylic acid) were from DuPont Merck
Pharmaceuticals (Wilmington, DE). ANG II and saralasin were pur-
chased from Sigma Chemical Co.; [125I]ANG II (2200 Ci/mmol) and
[3H]ANG II were purchased from Amersham International (Amer-
sham International).
Results
[125I]ANG II autoradiography
[125I]ANG II labeled a saturable binding site in 20-mm sections
of human placenta (Fig. 1). Specific binding (defined by the in-
clusion of unlabeled ANG II, 1.0 mM) was associated mainly
with the AT1 receptor since it was sensitive to the inclusion of
losartan (Fig. 1). The specific losartan-sensitive binding repre-
sented mean (6SD) 8069% of the total binding. In contrast,
the AT2 receptor–specific ligand competed for only 666% of
the total binding (Fig. 2 A). In addition to losartan- and
PD123177-sensitive specific [125I]ANG II, an additional high
affinity binding site was consistently detected that was insensi-
tive to both losartan (1 mM) and PD 123177 (1 mM) and repre-
sented z 15610% of the total binding.
Western blot and binding studies of AT1 receptors in IUGR
AT1 receptor binding was significantly reduced (P , 0.02) in
IUGR pregnancies with reduced or absent end-diastolic flow
velocity (Fig. 2 A). Western blot analysis confirmed the bind-
ing studies and showed quantitatively a marked reduction in
AT1 receptor protein in IUGR compared with normal placen-
tae (Fig. 2 B). The anti-AT1 receptor antibody recognized a
major band of 60 kD and a minor band of z 45 kD. The antise-
rum was able to detect specific bands whose molecular size
was consistent with the predicted molecular mass of the glyco-
sylated AT1 receptor based on the amino acid sequence.
Figure 1. Autoradiograms of the distribution of [125I]ANG II bind-
ing to adjacent sections (20 mm) of the human term placentae. Dark 
regions indicate high densities of labeled receptors. (A) Total bind-
ing; (B) binding in the presence of the AT1 receptor-selective 
ligand DuP753 (1.0 mM); (C) binding in the presence of the AT2 
receptor-selective ligand PD123177 (1.0 mM); (D) binding in the 
presence of DuP753 (1.0 mM) plus PD123177 (1.0 mM); (E) binding 
in the presence of unlabeled ANG II (1.0 mM); (F) histological sec-
tion of term placenta. The difference in density between A and B 
represents AT1 receptor specific binding; difference in density be-
tween A and C represents AT2 receptor specific binding; difference 
between A and D represents specific AT1 plus AT2 receptor density 
and the difference between D and E represents the non-AT1/non-
AT2 novel ANG II recognition site. Bar, 30 mm.
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[3H]ANG II homogenate binding to placental membranes
ANG II at nanomolar concentrations, competed in a mono-
phasic manner for [3H]ANG II binding to placental mem-
branes (IC50 4.860.64 nM; Fig. 3 A). Specific binding (defined
by the inclusion of ANG II, 1.0 mM) represented z 95–
100% of the total binding. Losartan also competed for
[3H]ANG II binding to placental membranes (IC50 92.8615.4
nM; Fig. 3 A) while PD123177 at concentrations up to 10 mM
failed to compete for [3H]ANG II binding (Fig. 3 A).
In the presence of 1.0 mM PD123177, there was no reduc-
tion in the total specific binding. Both ANG II and losartan
competed for [3H]ANG II binding in a monophasic manner
(Fig. 3 B) completely displacing [3H]ANG II binding at 1 and
10 mM, respectively. Hill coefficients tended towards unity
(Hill coefficient ANG II 0.77360.11; losartan 0.8960.03) while
IC50 values were 1.9460.1 and 60.5612.6 nM for ANG II and
losartan, respectively.
Localization of mRNA encoding AT1 receptor
In situ hybridization was performed in order to identify the site
of expression of AT1 receptor mRNA in first trimester (n 5 7)
and term placentae (n 5 10). In first trimester (12 wk gesta-
tion) AT1 receptor mRNA hybridization signal was localized
in the cytotrophoblast (Fig. 4, bold arrows) and syncytiotro-
phoblast of the villi (Fig. 4, A and B). When tissue sections
were incubated with 35S-labeled probe along with 100-fold ex-
cess of unlabeled probe in the hybridization buffer, the hybrid-
ization signal was substantially lower under these conditions
compared with hybridization produced by the labeled probe
alone (Fig. 4, C and D).
At term, AT1 receptor mRNA localization was performed
using both radiolabeled and nonradioactive probes as the lat-
ter method ensured that the villous structures were more
clearly distinguishable. AT1 receptor mRNA was localized in
the syncytiotrophoblast of the terminal villi (Fig. 5, A and B)
but the endothelium of the villous capillary expressed no de-
tectable AT1 receptor mRNA hybridization signal (Fig. 5 B).
The highest level of AT1 mRNA was localized in the brush
border of the syncytiotrophoblast (the specificity of the signal
was negligible in RNAse pretreated sections; Fig. 5 C). Simi-
larly, using radiolabeled probes, AT1 receptor mRNA hybrid-
ization signal was detected in the syncytium of term placentae
(Fig. 6, A and B). Weak AT1 receptor mRNA expression was
noted in the amnion, whereas the chorio-decidua showed
strong hybridization signal for AT1 receptor mRNA (Fig. 6, G
and H). The specificity of the signal was further confirmed by
incubating labeled probe along with 100-fold excess of unla-
beled probe in the hybridization buffer which demonstrated
that the hybridization signal was markedly lower under these
Figure 2. (A) The levels of specific [125I]ANG II binding sites in
human normal and IUGR placentae. Data represents the mean
(6SEM) of AT1-, AT2-, and non-AT1/non-AT2–specific binding in 
specimens from normal (filled column; n 5 12) and IUGR (hatched 
column; *P , 0.05, n 5 7) placentae. (B) Enhanced chemilumines-
cence Western immunoblotting of AT1 receptor in normal and IUGR 
placental protein lysates. Equal amount of total protein for each sam-
ple was loaded from normal (n 5 3) and IUGR (n 5 3) placentae. 
The human AT1 receptor antibody recognized a major band of 60 kD 
and a minor band corresponding to z 45 kD. Both these bands were 
markedly reduced in IUGR.
Figure 3. Ability of peptide and nonpeptide AT receptor ligands 
alone (A) and in the presence of 1 mM PD123177 (B) to compete for 
the binding of [3H]ANG II to membranes prepared from the human 
placenta. Data fitted to a one-site model. The values represent the 
mean6SEM of three separate experiments.
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conditions compared with the signal produced by the labeled
probe alone (Figs. 5 D  and 6, C and D). In addition, pretreat-
ing with 100 mg/ml of RNAse A markedly reduced the hybrid-
ization signal (Fig. 6, E and F) confirming specificity of the
AT1 receptor probe.
The intensity of the hybridization signal for AT1 receptor
over the syncytium was reduced in IUGR (Fig. 7, C and D,
n 5 6) compared with normal (Fig. 7, A and B, n 5 10) placen-
tae. In the media of the stem vessels, AT1 receptor mRNA sig-
nal was apparently increased in the IUGR cases (Fig. 7, G and
H) as compared with normal placental vessels (Fig. 7, E and F).
Localization of AT1 receptor protein
Intense immunostaining for AT1 receptor was observed in the
cytotrophoblast and syncytiotrophoblast of first trimester (12
wk gestation; Fig. 8, A and B) and in the CD68-positive Hof-
bauer (H) cells (Fig. 8 B) while weak AT1 receptor immuno-
protein was detected in the CD31-positive endothelial cells of
Figure 4. Localization of AT1 re-
ceptor mRNA in human early 
gestational placental villi. Photo-
micrograph shows in bright field 
(A) intense signal in the cytotro-
phoblast (bold arrows) and syn-
cytiotrophoblast of the villi in 
first trimester (12 wk gestation) 
placental section hybridized with 
35S-labeled oligonucleotide di-
rected against AT1 receptor. The 
signal is seen as silver grains in 
the same field visualized with 
dark field optics (B). The arrow-
head indicates the trophoblasts 
lining the villi. When tissue sec-
tions were incubated with
35S-labeled probe along with 
100-fold excess of unlabeled 
probe in the hybridization 
buffer, the hybridization signal 
was substantially lower under 
these conditions (C and D) com-
pared to hybridization produced 
by the labeled probe alone. Bar, 
50 mm.
Figure 5. Localization of AT1 re-
ceptor mRNA in human term 
placenta. A shows intense signal 
in the syncytiotrophoblast (Syn) 
of placental section hybridized 
with fluorescein-dUTP–labeled 
oligonucleotide directed against 
AT1 receptor; B shows lack of 
expression of AT1 mRNA in or 
around the fetal blood vessels 
(bv); C indicates RNAse-treated 
serial section showing no hybrid-
ization signals around blood ves-
sels (bv); and D shows reduced 
hybridization signal after excess 
cold labeling. Bar, 50 mm.
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the villous capillary (Fig. 8, A and B). The decidual (Fig. 8 C)
and cytokeratin-positive extravillous  cells (Fig. 8 D) showed
strong staining for AT1 receptors. At term, AT1 receptor im-
munoprotein was localized to the syncytium, endothelial cells
of the villous capillary network, and to smooth muscle of pla-
cental blood vessels higher up the vascular tree (Fig. 8 E). The
control section in which the primary anti-AT1A receptor anti-
body was preabsorbed overnight with the synthetic peptide
fragment (1:100) showed negligible staining (Fig. 8 F).
Effect of ANG II on nitric oxide production
Consistent with activation of a constitutive isoform of NOS,
NO formation increased rapidly in response to 10 nM ANG II,
exceeding basal release within 15 s, the earliest time point
measured (P , 0.01, n 5 2; Fig. 9 A) and reached a maximum
within 2 min of stimulation (P , 0.01, n 5 2). Thereafter, total
NO levels plateaued but remained elevated. In contrast, addi-
tion of 10 ng/ml vascular endothelial growth factor (VEGF), a
tyrosine kinase activator, caused a less rapid generation of NO
Figure 6. Localization of AT1 re-
ceptor mRNA in term placental 
villi and fetal membranes. Pho-
tomicrograph shows in bright 
field (A) intense signal in the 
syncytium hybridized with
35S-labeled oligonucleotide
directed against AT1 receptor. 
The signal is seen as silver grains 
in the same field visualized with 
dark field optics (B). When tis-
sue sections were incubated with 
35S-labeled probe along with 
100-fold excess of unlabeled 
probe in the hybridization 
buffer, the hybridization signal 
was substantially lower and neg-
ligible around the blood vessels 
(bv) under these conditions (C 
and D). E and F indicate 
RNAse-treated serial section 
showing weak hybridization sig-
nals. G and H show localization 
of AT1 receptor mRNA in feto-
placental membranes. Weak sig-
nal was seen in the amnion 
(amn) and strong hybridization 
was detected in the chorio-
decidua (chor). Bar, 50 mm.
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release and reached a maximum at 10 min of stimulation that
was sustained over a 30-min time period (Fig. 9 A).
The concentration-dependency of ANG II–stimulated NO
release from trophoblast cells over a 30-min period is shown in
Fig. 9 B. The increase in total NO evoked by ANG II within
the concentration range tested (0.1 nM–10 mM) was almost
abolished by the inclusion of 0.1 mM of the competitive NOS
inhibitor L-NNA at the time of stimulation (Fig. 9 B). Stimula-
tion of the trophoblast cell line with 10 nM ANG II in the pres-
ence of external calcium evoked a significant increase in total
NO with values typically 63.063.2% above basal (P , 0.001,
n 5 3). In contrast, when stimulations were conducted in the
presence of low calcium buffer (150 nM), ANG II failed to
stimulate a significant release of NO, indicating dependency
on extracellular calcium (P , 0.001, n 5 3).
To identify which AT receptor subtype was responsible for
the ANG II–mediated NO release, the trophoblast cells were
stimulated with either ANG II alone or in the presence of ei-
ther the AT1-specific receptor antagonist losartan (DuP753) or
the AT2-specific receptor antagonist PD123177 (alone and in
Figure 7. Localization of AT1 re-
ceptor mRNA in normal and 
IUGR placentae. A and B show 
intense signal in the syncytium 
(ST, bold arrows) of normal pla-
cental section hybridized with 
35S-labeled oligonucleotide di-
rected against AT1 receptor. C 
and D show reduced expression 
of AT1 mRNA in the syncytium 
of IUGR placentae. E and F 
show hybridization signal around 
fetal blood vessels (bv) in nor-
mal placental and G and H show 
increased signals around blood 
vessels in IUGR. Bar, 50 mm.
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combination). ANG II (100 nM)–stimulated NO release was
not prevented by either losartan or PD123177 alone or when
combined (Fig. 10). ANG II–mediated NO release was inhib-
ited when the concentration of the two antagonists (losartan
and PD123177) were applied in combination and their concen-
trations were raised to 10 mM (P , 0.05; Fig. 10). ANG II stim-
ulated NO release at a range of ANG II concentrations (0.1–10
mM), whereas at the higher concentrations of ANG II, losar-
tan or PD123177 still failed to antagonize the NO release (Fig.
11, A  and B). Although at nonphysiological concentrations of
ANG II (1–10 mM), the further elevation of NO release was
prevented by combined application of losartan and PD123177
(Fig. 11 C).
Placental explant studies
In vitro explants of amnion chorion and placenta (n 5 3) cul-
tured for 20 h in condition medium produced mean (6SD)
0.7660.09, 2.5160.22, and 0.1660.01 fmol PTHrP1–86 per mg
protein, respectively. After 20 h incubation at 378C, ANG II,
in a concentration-dependent manner, stimulated the release
of PTHrP1–86 (n 5 3) in condition medium from amnion (Fig.
12) and placental explants (Fig. 12). There was a twofold in-
crease in placental PTHrP production by ANG II (10 nM) and
from chorion, ANG II induced PTHrP1–86 release was in-
creased to 3.6360.77 at 100 nM (data not shown).
Discussion
This study shows the localization of AT1 receptor mRNA and
protein in cytotrophoblast and syncytiotrophoblast in placen-
tal villi during early and late pregnancy using in situ hybridiza-
tion and immunocytochemistry, respectively. It also demon-
strates that AT1 receptor mRNA and protein is reduced in
IUGR placenta and shows that ANG II (100 nM) can stimu-
late vasorelaxants such as NO and PTHrP. It confirms the ear-
lier work of Kingdom et al. (36) who states that human term
placenta contains predominantly AT1 receptor binding sites
with low levels of AT2 receptor binding sites. Although spe-
cific receptor binding sites for ANG II were identified in pla-
cental vascular smooth muscle homogenates (37) and AT1 re-
ceptor binding sites in membrane homogenates of vascular
tissue from human term placenta (36), a novel aspect of this
study is that it shows that human trophoblast contains AT1 re-
ceptors and that an apparently additional high affinity non-
AT1/non-AT2 ANG II recognition site is identified in human
placenta that may be responsible for ANG II–mediated NO
Figure 8. Immunolocalization 
of AT1 receptor throughout 
pregnancy.  A shows first trimes-
ter villi (12 wk), and B shows 
placental villi at 24 wk stained 
with anti-AT1A receptor anti-
body raised against the synthetic 
peptide corresponding to amino 
acids 15–24 of the rat AT1A re-
ceptors . Strong staining is seen 
in the cytotrophoblast shell (A, 
Cyt arrowhead) and weaker 
staining in syncytiotrophoblast 
layer (A, Syn arrowhead).  B 
shows staining in Hofbauer cells 
within the villous mesenchyme 
(B, H arrowhead). C–E show 
term placenta. In  C, D, and E, 
positive immunostaining was de-
tected in the bilayer of syncy-
tiotrophoblast and cytotropho-
blast, in the endothelium of fetal 
blood vessels (BV), the decidual 
cells (DEC), and the extravillous 
trophoblast (EVT) in the mater-
nal bed.  F is control in which the 
primary anti-AT1A receptor anti-
body was preabsorbed over-
night with the synthetic peptide 
fragment (1:100). (A, B, C, E, F) 
3284; (D) 3142 .
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and PTHrP. This study is the first to show that the high levels
of AT1 receptor mRNA and protein are localized in the cy-
totrophoblast and syncytiotrophoblast of first trimester pla-
cental villi, and that AT1 receptor immunoprotein expression
is present in endothelial cells of the villous capillary network
and the smooth muscle of placental blood vessels higher up the
vascular tree.
One of the important functions of the human placenta is to
produce peptide hormones during pregnancy. The differenti-
ated syncytiotrophoblast has endocrine properties including
secretion of human chorionic gonadotrophin and human pla-
cental lactogen (38). The high levels of AT1 receptor mRNA
together with localization of its AT1 receptor protein in syncy-
tiotrophoblast, suggest that ANG II may be involved in secre-
tory functions as well as vasoregulation. This view is supported
by a recent report that announced that ANG II stimulates es-
tradiol-17b secretion from placental explants via AT1 receptor
activation (39). Formation of estriol, the end product of estra-
diol-17b oxidation, reflects feto-placental function (40). The
reduced levels of placental AT1 receptors in severe IUGR
compared with normal pregnancy may account for reduced es-
triol reported in this disorder. Abnormal Doppler waveforms
in the umbilical artery suggest that increased downstream im-
pedance is associated with depleted numbers of arteries and
arterioles in the tertiary stem villi in IUGR (41). The reduced
levels of AT1 receptors is likely to be as a consequence of
chronic activation of the placental renin–ANG system in
IUGR, however, the possibility that it may simply be a reflec-
tion of reduced villous tree elaboration and poor villous mor-
phology can not be excluded.
Syncytiotrophoblast surrounding the placental villi express
the potent angiogenic factors, such as basic fibroblast growth
factor (FGF-2) and VEGF (for review see reference 42). Ad-
ministration of ANG II to chick embryo chorioallantois mem-
brane induced pronounced neovascularization via an “un-
known AT receptor” subtype (43) and ANG II stimulates
expression of FGF-2 in bovine luteal cells (44). Using quantita-
tive receptor autoradiography and competition with selective
AT receptor antagonists, a high affinity ANG II recognition
site was shown to be pharmacologically distinct from the cur-
rently known AT receptor subtypes since it was insensitive to
AT1 or AT2 receptor-selective ligands at relevant concentra-
tions. It is possible that the angiogenic properties of ANG II
may relate to the production of these factors via the non-AT1/
non-AT2 binding site. However, the presence of this non-AT1/
non-AT2 binding site was not supported by the binding studies
on placental membrane homogenates. There was a small dif-
ference in the percentage of the radiolabeled ANG II binding
Figure 9. Kinetic and dose dependency of ANG II–evoked nitric ox-
ide release. (A) Cells were incubated with 10 nM ANG II (ANG II, 
filled circle) or 10 ng/ml vascular endothelial growth factor (VEGF, 
open circle) for defined time points. (B) Cells were incubated with in-
creasing concentration of ANG II for 30 min in the presence (open 
circle) or in the absence (filled circle) of 0.1 mM L-NNA and the su-
pernatants were removed and assayed for NO using a Sievers NOA 
chemiluminescence analyzer. The appropriate controls (medium 
alone and medium plus cells) were subtracted from experimental re-
sults. Data represents mean6SEM of a single experiment, typical of 
three separate experiments.
Figure 10. Effect of subtype-selective ANG receptor antagonists on 
ANG II–evoked nitric oxide release. Cells were incubated for 30 min 
with 100 nM ANG II alone (square-hatched bars), with ANG II plus 
100 mM L-NNA (black bar), with 1 and 10 mM DuP753 (striped bars), 
with 1 and 10 mM PD123177 (gray bars), and with the two antagonists 
together at 1 mM (cross-hatched bars). Open columns show controls 
in the absence of ANG II. The supernatants were removed and as-
sayed for nitric oxide release. The appropriate controls (medium 
alone and medium plus cells) were subtracted from experimental re-
sults. Data represents mean6SEM of three separate experiments.
*P , 0.01 compared to ANG II–stimulated NO release.
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that was sensitive to the AT2 receptor ligand PD123177 be-
tween the two preparations (i.e., section or cell membranes of
placenta). This difference is more likely to arise from the dif-
ferent procedures used to demonstrate the sites. For instance,
tissue sections are likely to include cytosolic binding sites
whereas these will have been lost during the preparation of the
cell membranes for the homogenate studies. Thus, it is possible
that the non-AT1/non-AT2 binding site is within the cytosolic
compartment of placental tissue. Receptor autoradiographic
studies have identified similar high affinity ANG II recogni-
tion sites in human endometrium (12) and bovine placentae
(Schauser, K., personal communication). Although neither
losartan nor PD123177 alone were able to significantly inhibit
ANG II–evoked NO release, when cells were stimulated with
ANG II in the presence of 10 mM losartan and 10 mM
PD123177 in combination, ANG II–evoked NO release was
significantly inhibited. This suggests that ANG II could stimu-
late NO release via either AT1 or AT2 receptors as blockage of
both receptors are required to suppress the ANG II–evoked
NO response. Our work is supported by a recent demonstra-
tion of functional interaction between AT1 and AT2 receptors
in regulating electrophysiological responses of catecholamin-
ergic neurons (18). Both AT1 and AT2 receptors were able to
cause increases and decreases in neuronal delayed rectified
K1 current in response to ANG (100 nM; 18). It is also inter-
esting to note that the AT2 receptor was shown to mediate re-
nal production of NO in conscious rats (45).
Studies on isolated perfused human placental cotyledon
show that NO attenuates, and addition of NOS inhibitors po-
tentiates, the actions of vasoconstrictors in the feto-plancal cir-
culation indicating that NO has a role in maintaining placental
blood flow (26, 27, 28). However, the addition of NO to the in-
tervillous space, rather than to the feto-placental circulation it-
Figure 11. Competition curves using subtype-selective AT receptor 
antagonists on ANG II–evoked nitric oxide release. Cells were incu-
bated for 30 min with increasing concentrations of ANG II alone 
(AgII, open circles) in all experiments. Nitric oxide release (A) in the 
presence of losartan alone at 100 nM (filled circle), 1 mM (filled 
square), and 10 mM (open square); (B) in the presence of PD123177 
alone at 100 nM (filled circle), 1 mM (filled square), and 10 mM (open 
square); and (C) in the presence of losartan plus PD123177 at 100 nM 
(filled circle), 1 mM (filled square), and 10 mM (open square). The su-
pernatants were removed and assayed for NO release. The appropri-
ate controls (medium alone and medium plus cells) were subtracted 
from experimental results. Data represents mean6SEM of three sep-
arate experiments.
Figure 12. Concentration-dependent ANG II–evoked PTHrP release 
in amnion and placental explants. Amnion (open circle) and placental 
(filled circle) explants were incubated in serum-free medium for 2 h at 
378C in 95% air and 5% CO2. The explants were then exposed to in-
creasing concentration of ANG II for 20 h. The medium was removed 
and assayed for PTHrP in triplicate for each sample by a two-site 
IRMA with antibodies specific for residues 17–27 and 52–61 of 
PTHrP. The experiments were performed in triplicates for each dose 
and results are expressed as means (6SEM) of triplicate determina-
tion of one typical experiment.
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self, has no effect on perfusion pressure (46), suggesting that
trophoblast-derived NO may not have a significant influence
on the tone of feto-placental blood flow. In severe IUGR, the
placental mass is small relative to the fetus (41). Although high
levels of NO are cytotoxic, lower levels of NO may inhibit
growth of vascular smooth muscle (47) without toxic effects.
As ANG II stimulates smooth muscle cell proliferation, its
ability to stimulate trophoblast-NO may be to control the pro-
liferation of these cells. ANG II stimulates mRNA expression
of PTHrP, and PTHrP inhibits the stimulatory effects of ANG
II on DNA synthesis in rat aortic smooth muscle cells (48).
This suggests that PTHrP may also modulate the vasoactive
and growth-promoting effects of ANG II. The release of
PTHrP from placental explants, following stimulation with
ANG II further supports our premise that one of the role of
ANG II in the placenta may be to regulate placental growth by
second messengers, such as NO and PTHrP.
During the first trimester of normal pregnancy there is a
significant increase in plasma renin concentration (49), the en-
zyme that converts angiotensinogen to ANG I, the precursor
of ANG II. Interference with the renin–ANG system through
the use of ACE inhibitors appears to be associated with poor
pregnancy outcome and IUGR (50). The findings presented in
this study suggest that ANG II is likely to play a physiological
role in pregnancy and that the reduction in placental AT1
receptors in IUGR may, in part, account for poor placental
function in this disorder. This suggests, for the first time, the
existence of a cross-talk between AT1 or AT2 receptors in tro-
phoblast and that ANG II–stimulated NO and PTHrP may
modulate both growth and vascular tone in the placenta.
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